

1 **The association between periodontitis and the impact of oral health on the**
2 **quality of life of individuals with psoriasis and psoriatic arthritis**

3 Amanda Almeida Costa¹, Luís Otávio Miranda Cota¹, Rafael Paschoal Esteves
4 Lima¹, Alcione Maria Soares Dutra Oliveira², Sheila Cavalca Cortelli³, José
5 Roberto Cortelli³, Renata Magalhães Cyrino¹, Victor Silva Mendes¹, Tarcília
6 Aparecida Silva¹, Fernando Oliveira Costa¹

7

8 **Number of Words: 3,853; tables:6; supplementary figure:1; references:47**

9 **Corresponding author:** Fernando Oliveira Costa

10 Full Professor in Periodontics, School of Dentistry, Department of Dental
11 Clinics, Oral Pathology and Oral Surgery, Periodontology Division, Federal
12 University of Minas Gerais, Antônio Carlos Avenue 6627, Pampulha. PO Box
13 359 Zip Code 31270-901. Belo Horizonte, Minas Gerais – Brazil. Phone and
14 Fax number: +55 31 3284 2466. email: focperio@uol.com.br

15

16 **Conflict of interest and funding**

17 The authors declare having no conflicts of interest.

18

¹ Department of Dental Clinics, Oral Pathology, and Oral Surgery, School of Dentistry, Universidade Federal de Minas Gerais, Brazil

² Pontifícia Universidade Católica de Minas Gerais, Belo Horizonte, Brazil.

³ Department of Dentistry, Periodontics, Research Division, Universidade de Taubaté, São Paulo, Brazil

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

20 **ABSTRACT**

21 **Objective:** To evaluate the association between psoriasis (PSO), psoriatic
22 arthritis (PsA) and periodontitis (PE), and the Oral Health-Related Quality of Life
23 (OHRQoL) impacts on individuals with psoriatic disease's daily activities
24 compared to the non-psoriatic ones.

25 **Materials & Methods:** 296 individuals with psoriatic disease (PSO n= 210, APS
26 n= 86) (cases) and 359 without these diseases (controls) were included.
27 Complete periodontal examinations and collection of variables of interest were
28 performed. The Brazilian version of the *Oral Impacts on Daily Performance*
29 (OIDP) instrument was applied.

30 **Results:** The prevalence of PE was higher in PsA (57.0%; OR=2.67 95%CI
31 1.65–4.32; $p<0.001$) than in PSO (34.3%; OR=1.05 95% CI 0.73–1.51;
32 $p<0.001$) compared to controls (33.1%). Both PsA and PSO groups showed
33 more sites and teeth with 4-6mm probing depth (PD) and had higher OIDP
34 scores than controls ($p<0.001$), thus indicating worse self-reported quality of
35 life. PE, PSO+PE and consumption of alcohol/anxiolytics significantly influenced
36 OHRQoL ($p<0.05$). The influence of periodontal parameters on OHRQoL was
37 observed for the presence of PE; PD >6 mm; clinical attachment level >6 mm;
38 higher plaque index, % sites and teeth with bleeding on probing ($p<0.05$).

39 **Conclusion:** Negative impacts of PE on the OHRQoL were demonstrated. The
40 ones having PSO and especially PsA and PE presented significantly worse
41 indicators.

42 **Keywords:** psoriasis, psoriatic arthritis, periodontitis, quality of life.

44 **Introduction**

45 The term periodontal diseases encompass changes that affect
46 periodontal tissues which protect and insert the teeth, such as gingivitis and
47 periodontitis (PE). PE is characterized by host-mediated, microbiologically
48 associated inflammation, resulting in loss of periodontal attachment(1).
49 Susceptibility to PE is related to polymicrobial disorders that result in dysbiosis
50 considering its complex pathogenesis. The precise mechanisms that lead to the
51 onset of PE are not completely known yet, although studies have shown that PE
52 onset and progression depend on an imbalance in the individual's
53 immunoinflammatory response to dental biofilm microorganisms. Since the
54 presence of biofilm is essential but not sufficient for PE onset, the recognition of
55 microbial components by defense cells and the production of inflammatory
56 mediators is indeed crucial(2). This recognition can activate the acquired
57 immune response, leading to the differentiation of T-helper cells (Th) into Th1,
58 Th2, Th17 or T-regulatory cells (Treg)(3). Th1 and Th2 cells of the adaptive
59 immune system are the main agents in the pathogenesis of immune-mediated
60 diseases. Th17 cells and the cytokines IL-17 and IL-23 seem to play
61 fundamental roles(3).

62 Since the American Academy of Periodontology (1999) workshop
63 considerable evidence has emerged regarding potential effects of PE on
64 systemic diseases such as endocrine, cardiac, autoimmune disorders and
65 adverse pregnancy outcomes(4–6).

66 Psoriasis (PSO) is a chronic inflammatory skin disease characterized by
67 the inflammation of the dermis and epidermis. Its prevalence varies due to

68 country-specific variations and the methodological variability of epidemiological
69 studies, but in a global analysis, it has been outlined to vary from 0.14% to
70 almost 3%. Given the growing and the aging of worldwide population and the
71 fact that PSO primarily affects the adults, the burden associated with PSO may
72 continue to increase(7). Psoriatic arthritis (PsA) is a chronic inflammatory
73 musculoskeletal disease that has been defined as an inflammatory arthritis
74 associated with PSO and seronegative for rheumatoid factor. PsA occurs in 2-
75 3% of the general population, but among patients with PSO the prevalence
76 varies from 6% to 42%, with involvement of the skin, nails, bones, tendons,
77 ligaments, synovial membrane and joints(8,9).

78 Increasing evidence supports the association between PSO, PsA and
79 multiple comorbidities including obesity, metabolic syndrome, cardiovascular
80 disease, cerebrovascular disease, anxiety and depression (10,11) and PE
81 (6,12–15).

82 The hypothesis of an association between these diseases is that PE can
83 play a direct and indirect role in the development or exacerbation of psoriatic
84 disease, as both consist of a complex interrelationship between cell types of the
85 innate and acquired immune system, immunological factors produced by T
86 cells, dendritic and Th1-mediated cells, through the IL-23/IL-17 axis and
87 because they share some risk factors (e.g., diabetes and smoking) (16,17).

88 The relationship between PE, PSO and especially PsA has gaps and the
89 pathophysiological paths of this association are not completely elucidated. To
90 date, only 4 studies have been reported on the association of PE and PsA. (12–
91 14,18) Hence, literature is significantly scarce in relation to studies that address
92 the impact of OHRQoL of individuals with psoriatic disease.

93 This study is then justified by the need for greater knowledge about the
94 potential association between PSO, PsA and PE, and the similarities in their
95 comorbidities and risk factors, and also to seek a greater understanding of
96 OHRQoL of the affected individuals. Thus, we hypothesized that higher OIPD
97 scores are associated with the presence of worse periodontal clinical conditions
98 in individuals with psoriatic disease.

99 The aim of this case-control study was to evaluate periodontal status, its
100 clinical and epidemiological aspects and the impact of OHRQoL in PSO and
101 PsA individuals compared to those without psoriatic disease.

102

103 **Materials and Methods**

104 Sampling

105 The sample size calculation was based on a variation of around 10%
106 prevalence of PE among individuals with psoriatic disease, as reported by
107 Mendes *et al.*(19) and Mishra *et al.*,(13) and a PE prevalence of 30-40% among
108 controls and 50-60% among psoriatic individuals was assumed. The calculation
109 was performed using the Fleiss method, with continuity correction using
110 statistical software³. Based on a significance level of 0.05, 80% power and a
111 case-control ratio of 1:2, 77 cases and 153 controls were determined to be the
112 minimum required. However, during the data collection period (April 2020 –
113 December 2022), 655 individuals were examined and considered eligible. The
114 final sample consisted of 297 individuals in the case group, 210 individuals with
115 PSO and 86 with PsA, and 359 without psoriasis (controls).

³ Open Epidemiologic Statistics for Public Health, version 3.01, Boston, MA, USA.

116 PSO individuals were selected from those undergoing treatment and
117 monitored at the Department of Dermatology at Hospital Eduardo de Menezes,
118 and at the Center for Specialized Medicine, Teaching and Research in Belo
119 Horizonte, Brazil, from March 20, 2020 until July 30, 2022. The control group
120 consisted of individuals without any dermatological disease, selected from
121 relatives, companions or employees of the respective reference centers.

122 The following inclusion criteria were established: individuals aged 35 to
123 65 years, presence of ≥ 14 teeth(20) and absence of contraindications for clinical
124 periodontal examination. Exclusion criteria included individuals undergoing
125 antibiotic therapy or periodontal treatment over the last three months. During
126 clinical periodontal examinations, third molars were included only when in the
127 position of second molars (19).

128 This study was approved by the Research Ethics Committee from the
129 Federal University of Minas Gerais – Brazil (#CAAE 20156019.0.0000.5149)
130 and followed the 1975 Declaration of Helsinki as revised in 2013. All
131 participants were informed about the study procedures and signed a consent
132 form before participating in the study.

133

134 Variables of interest

135 The following variables of interest were collected during the interviews:
136 gender, age, family income, educational level, flossing (yes/no), toothbrushing
137 frequency (times/day), body mass index (BMI), diabetes(21), use of anxiolytics
138 and antidepressants, smoking(22) and alcohol consumption (yes,
139 no/occasional).

140 Quality of Life assessment

141 A Brazilian version of the *Oral Impacts on Daily Performance* (OIDP)
142 questionnaire was applied to assess OHRQoL (23,24). It assesses the
143 frequency and severity of oral impact on individuals' daily performances, as
144 such: (1) physical performance (eating and enjoying food, speaking and hearing
145 clearly, teeth cleaning); (2) psychological performance (sleeping and relaxing,
146 smiling showing teeth without embarrassment, maintaining balanced emotional
147 state); (3) social performance (throughout their main job or social role, enjoying
148 contact with people). The occurrence of any difficulty is recorded dichotomously
149 (yes/no) and the frequency is indicated by the duration period with the following
150 scores: (1) lesser than once a month, or an interval of up to 5 days total; (2)
151 once or twice a month, or an interval of up to 15 days total; (3) once or twice a
152 week, or an interval of up to 30 days total; (4) three or four times a week, or an
153 interval of up to 3 months total and (5) every or almost every day, or an interval
154 of more than 3 months total. Regarding severity, it varies between “no severity”
155 (0) and “extremely severe” (5). The maximum score is 200 and it is equivalent
156 to multiplying the frequency by the severity, with the final score given by the
157 sum of the difficulties reported in the 8 categories (200= 8 categories x 5
158 frequencies x 5 severity scores). The higher the score, the worse the OHRQoL
159 is shown.

160 Clinical periodontal examination

161 The level of oral hygiene was assessed using the plaque index (PI) (25).
162 Scores for each site were added and mean values were recorded per tooth and
163 individual. Periodontal parameters were then evaluated in all teeth, and values

164 for each of the four sites (mesial, distal, buccal and lingual) were recorded:
165 probing depth (PD), clinical attachment level (CAL), bleeding on probing (BOP).
166 A manual periodontal probe model UNC-15, a clinical mirror and gauze were
167 used.⁴

168

169 Intra and inter-examiner agreement

170 Examinations, interviews and the OIDP questionnaire application were
171 conducted by three experienced and trained periodontists (AAC, FOC and
172 VSM). Intra- and inter-examiner agreements for periodontal examinations were
173 performed in a pilot study with 12 individuals using the Kappa test and the
174 intraclass correlation coefficient (ICC). The Kappa values for PD and CAL were
175 >0.93 and the ICC >0.90.

176 Definition and staging of periodontitis

177 Stages I, II, III and IV were included, according to the Tonetti *et al* (2018)
178 criteria (1).

179 Diagnosis of psoriasis and psoriatic arthritis

180 The diagnosis and severity of the disease (mild, moderate or
181 advanced) were established by the group of dermatologists associated with the
182 reference centers.

183 The psoriasis area and severity index (PASI)(26) was used and made
184 available in all medical records. The PASI examines four regions of the body: (I)
185 head and neck, (II) hands and arms, (III) chest, abdomen and back (trunk) and
186 (IV) buttocks, thighs and legs. Each region is given a score to show how much

⁴ UNC-15, Hu-Friedy, Chicago, IL, USA.

187 each is affected by PSO (area) and another for how bad the PSO is (severity).
188 The area score can range from 0 (no psoriasis) to 6 (all skin affected). Each
189 region's severity score is evaluated by adding redness, thickness, and scale
190 scores, each of which is rated from 0 to 4, with a maximum of 12. The following
191 cutoffs are used for severity: <7 mild, 7–12 moderate and >12 advanced
192 psoriasis.

193 For the PsA diagnosis, The CASPAR criteria (27) was used: presence
194 of confirmed inflammatory joint disease (joints, spine, or entheses); with at least
195 three of these elements: current PSO, history of PSO or family history of PSO;
196 dactylitis; bone formation in articular area (hands/feet); negative rheumatoid
197 factor and psoriatic nail dystrophy. The sensitivity and specificity of the CASPAR
198 criteria are 99.7% and 99.1%, respectively.

199

200 Statistical analysis

201 Initially, the groups were compared in relation to the following
202 variables: gender, age, family income, educational level, use of dental floss,
203 BMI, diabetes, continuous use of anxiolytics, antidepressants, smoking and
204 alcohol consumption using Chi-square, Fischer and Mann-Whitney tests when
205 appropriate. Regarding periodontal parameters (IP, BOP, PD, CAL) the values
206 per individual were obtained by summing the measurements from all
207 periodontal sites and expressed as means and/or percentages.

208 An indicator was created in relation to OHRQoL, calculating the
209 product between frequency and severity, multiplied by 100 and divided by 200.
210 In the descriptive analysis of qualitative variables, absolute and relative

211 frequencies were used, while for quantitative variables, measures of position,
212 central tendency and dispersion were used. To compare categorical variables
213 regarding QoL indicators, the Mann-Whitney and Kruskal -Wallis tests were
214 used. The analysis of the frequency and severity of indicators of difficulty in
215 carrying out daily activities using the OIDP are presented in Bootstrap intervals
216 with a 95% confidence interval (CI). When the CI of an item does not overlap
217 with one of another item within a group, there is statistical evidence that the
218 items mean are statistically different. The software used in the analyzes was R.⁵
219 Results with $p < 0.05$ were considered significant.

220

221 **Results**

222 The sample consisted of 210 psoriasis individuals (PSO), 86 with PsA
223 and 359 controls, 407 women and 248 men, with a mean age of 47.5 (± 5.1)
224 years for the control group, 49.7 (± 4.2) years for the PSO group ($p < 0.001$); and
225 48.8 (± 4.3) for the PsA group ($p = 0.011$) (Table 1). Regarding variables of
226 interest, PSO individuals presented significantly higher values of the occurrence
227 of diabetes ($p = 0.004$), alcohol consumption ($p = 0.001$), antidepressants
228 ($p = 0.006$) and anxiolytics ($p = 0.008$), as well as higher BMI ($p < 0.001$) (Table
229 1) when compared to controls. PsA individuals also showed greater
230 antidepressants ($p < 0.001$) and anxiolytics use ($p = 0.013$), diabetes ($p = 0.002$)
231 and higher BMI ($p < 0.001$) compared to controls. In addition, data demonstrated

⁵ R software originally created by Ross Ihaka and Robert Gentleman, University of Auckland, New Zealand (version 3.6.1).

232 PsA individuals had greater alcohol (p=0.040) and antidepressants (p=0.036)
233 consumption than PSO individuals.

234 Table 2 shows the comparison between groups regarding periodontal
235 parameters. PsA individuals showed significantly more PE (57.0%; OR=2.67,
236 95%CI: 1.65-4.32 p<0.001), while PSO (34.3%; OR=1.05; 0.73-1.51; p<0.001)
237 than controls. PsA and PSO group revealed a greater number of sites and teeth
238 with PD 4-6mm than controls (p<0.001). PD mean in PsA was significantly
239 higher than in PSO (p=0.004) and controls (p=0.001), as well as in the
240 comparison between PSO and controls (p<0.001). CAL frequency of >6mm was
241 higher in PsA group, and significantly higher than in PSO group (p<0.001) and
242 controls (p=0.001). Regarding BOP, higher mean values were observed in PsA,
243 followed by PSO and controls (PsA>PSO>Controls; p<0.001) and
244 (PSO>controls; p=0.034)]. As for IP; PsA group presented significantly higher
245 and worse scores than those reported in the PSO group (p=0.001) and controls
246 (p<0.001).

247 When analyzing OHRQoL, PsA group presented a significantly higher
248 mean impact (p= 0.011) than controls (Supplementary Figure 1). Interestingly,
249 when using the OIDP stratification into no impact (0), low (1-15), medium (16-
250 45) and high (45-200) scores a significant difference was identified among PSO
251 and PsA individuals, who have a higher mean of high OIDP scores when
252 compared to controls (p<0.001). High OIDP scores indicate worse OHRQoL.

253 Table 3 shows the characterization of individuals regarding each OIDP
254 activity, in frequency and severity. A significant difference exists when there is
255 no overlap between CI as in the comparison of the frequency of discomfort
256 when speaking between patients with and without PE in the control group: those

257 with PE experienced discomfort when speaking more frequently than those
258 without PE. It is observed that in the control and PSO groups, 11 items do not
259 overlap, indicating a significant difference between them, and that they are
260 worse in the presence of PE. In the PsA group, the situation is reversed and 11
261 items overlap. This result may suggest that PsA disease is more debilitating and
262 has a greater impact on the individual's overall QoL, so that they feel and report
263 less discomfort in the presence of PE or even worry less about their oral
264 condition.

265 When evaluating the influence of variables of interest on QoL in a
266 dichotomous manner (without/with impact), Table 4 shows that alcohol and
267 anxiolytics use, presence of periodontitis, and psoriasis with periodontitis were
268 significant ($p < 0.001$). In the final logistic regression model, PE ($p < 0.001$) and
269 alcohol/anxiolytic use ($p = 0.002$) remained significantly (Table 5).

270 Regarding periodontal parameters influence on QoL (Table 6), a
271 significant difference was observed for the presence of PE; PD > 6mm; CAL
272 >6mm ($p < 0.001$); higher plaque index ($p = 0.002$), higher BOP % of sites
273 ($p = 0.005$) and teeth ($p = 0.006$). There was a higher PD < 3mm (41.6%)
274 percentage of sites in individuals without impact and sites with PD > 6mm in
275 individuals with impact (3.1%) ($p < 0.001$). Also, higher PD > 6mm % of teeth
276 (8.1% - $p < 0.001$) in individuals with impact, with the same occurring for CAL >
277 6mm [% of sites (8.4%) and teeth (14.5%) - ($p < 0.001$)]. These data
278 demonstrated that a worse clinical periodontal condition had a negative impact
279 on the analyzed individuals' OHRQo (Table 6).

280

281 Discussion

282 The present study demonstrated a risk association between PSO and
283 PE, with PsA individuals having significantly worse OHRQoL indicators. A
284 significantly higher PE prevalence was observed among PsA individuals (57%)
285 when compared to controls (33.1%). In PSO (34.35%), the comparison was not
286 significant despite the higher prevalence. PsA individuals had a 2.67 greater
287 chance of developing PE than controls (OR =2.67; $p<0.001$). Additionally, they
288 presented a significantly worse periodontal clinical condition, expressed by
289 higher means of PI, BOP, PD, CAL as well as % of sites with PD 3-6 mm and
290 >6 mm.

291 A high prevalence of PE in psoriatic disease individuals is reported in
292 several studies,(12–14,19,28–30) most of which addressed PSO. The literature
293 does not always categorize PSO and PsA conditions separately. Most studies
294 address PSO and some encompass PsA, (12–14,18) referring to these two
295 categories of disease uniquely in their discussion, using terms such as
296 “psoriatic disease” or even “psoriasis group”. This fact directly impacts the
297 possibility of better understanding the prevalence of PE, specifically in PsA.
298 However, within the available literature, when separately evaluating PSO and
299 PsA, the high prevalence of PE in our study (57%) in PsA is very similar to the
300 literature, as reported in the recent study by Mishra *et al* .(13) [(PsA (58.18%)
301 vs. control (42.72 – $p=0.042$)]. Due to this gap in the literature, it is of high
302 relevance that new studies should aim at individuals with PsA to better elucidate
303 whether their possible greater immune vulnerability puts them at greater risk for
304 PE, credited to the fact of greater severity of psoriatic disease.

305 Regarding the worse periodontal condition of PSO individuals, our
306 findings corroborate other recent and robust studies reported (12,14,19,28). Our
307 definition of “robust” was based on full-mouth examinations, significant samples
308 and well-defined criteria for PE and psoriatic disease, bringing greater reliability
309 to the findings.

310 A possible association between PE and increased risk of immune-
311 mediated inflammatory diseases has been increasingly recognized. Although
312 the biological mechanism that explains the increased risk of psoriatic disease
313 among individuals with PE is unknown, several hypotheses have been
314 proposed. One is related to its shared pathology, since exaggerated immune
315 responses to the microbiota present on the epithelial surface are observed in
316 both conditions, suggesting a genetic predisposition that affects dendritic cells
317 and the expression of toll-like receptors (9,16,31,32). Therefore, these
318 pathologies (PE, PsA and PSO) are immune-mediated and present similar
319 etiopathogenic pathways, involving greater susceptibility of an individual with an
320 immune response deficiency and common risk factors.

321 Observational studies have also confirmed findings of the association
322 between PE and psoriatic disease (12,18,19). However, it is worth mentioning
323 some limitations of these studies, such as: (i) use of retrospective data obtained
324 from medical records(12,14); (ii) use of periodontal indexes to define
325 PE(18,28,29); (iii) small samples(18,28,29); (iv) self-reported information on
326 periodontal conditions and PSO(29,33) and (v) causality bias, as the diseases
327 share numerous risk factors (e.g. smoking and diabetes) (6,15). To date, these
328 limitations may together be an important factor in the presence of conflicting
329 results and moderate evidence for an association between these diseases.

330 This study demonstrated that individuals with PSO and PsA showed
331 significantly higher BMI values, anxiolytics/antidepressants use and occurrence
332 of diabetes than controls. Those with PSO had greater alcohol consumption
333 than controls ($p=0.001$), and those with PsA had greater alcohol ($p=0.040$) and
334 antidepressants ($p=0.036$) use than PSO individuals. These data corroborate
335 previous findings, since these variables can contribute to systemic triggers
336 activation leading to immunological changes (exacerbation in the expression of
337 cytokines), endocrine and behavioral disorders (lack of hygiene, smoking and
338 other harmful habits) which can predispose greater susceptibility to these
339 diseases (4).

340 It is noteworthy that mood disorders (particularly depression) have
341 been suggested to be significantly more prevalent in PSO individuals (up to
342 62%) than in the general population (4 to 10%)(10). Other mental health
343 comorbidities such as anxiety and suicidal ideation have been reported to be
344 more prevalent in psoriatic disease individuals (34).

345 Contributing factors for this higher prevalence have been reported as:
346 (1) the disease physical impact, with compromised dermal integrity and
347 symptoms such as pain, itching, joint stiffness (35); (2) the clinical signs of the
348 disease, such as skin disfigurement, negatively and directly impacting self-
349 perception of one's own body (35) and (3) psychiatric disorders that may result
350 in and contribute to the progression of psoriatic disease, suggesting that
351 psoriatic disease and psychiatric conditions (e.g. depression) may have
352 overlapping biological mechanisms – explained by an inflammatory model
353 (10,34).

354 Several studies have reported that PSO strongly influences global QoL
355 of psoriatic individuals(36–38) and a recent systematic review indicates a higher
356 prevalence of depression and anxiety in PsA, demonstrating worse QoL of
357 these individuals(39).

358 As evidence suggests that psoriatic patients have worse oral conditions
359 and worse periodontal parameters, it can be assumed that the QoL of these
360 individuals is even more negatively affected by oral changes. Literature already
361 corroborates to the fact that oral conditions such as pain, cavities, tooth mobility
362 and tooth loss, have negative effects on the well-being of individuals, especially
363 in those with PE (38,40).

364 However, this is the first study that addresses OHRQoL in PsA
365 individuals to date, particularly targeting periodontal condition. Only one recent
366 study(41) evaluated OHRQoL in PSO. The authors reported a risk association
367 between PSO and PE, with individuals with both diseases having significantly
368 worse OHRQoL indicators. In addition, PE and PSO severity significantly
369 increased these negative effects.

370 The hypothesis proposed in the study that individuals with PsA and PE
371 would present worse OHRQoL indicators was confirmed. Results demonstrated
372 that PsA group had significantly higher mean impact on OHRQoL ($p= 0.011$)
373 than the controls. A significant difference was identified among PsA and PSO
374 individuals, who had higher means of high OIDP scores when compared to
375 controls ($p<0.001$). High OIDP scores indicate worse QoL. These data reinforce
376 the existing, albeit scarce, literature on the impact of psoriatic disease on
377 OHRQoL (38,41).

378 A higher percentage of individuals with an impact on QoL was
379 observed in those with PE (45.8%) when compared to those without PE (28.7%)
380 when evaluating QoL and periodontal parameters. Thus, our findings
381 corroborate those of negative impacts of PE on OHRQoL, reinforcing the
382 literature that points out that worse periodontal conditions negatively and
383 significantly affect individuals' routine activities. Literature reports studies using
384 the OIDP to assess OHRQoL (40–43) while others used different instruments,
385 such as the Oral Health Impact Profile questionnaire (OHIP-14) (44,45).

386 Some limitations must be attributed to the present study. The main one
387 being inherent to a case-control study which does not demonstrate a causal link
388 due to temporality; with our data, it is not possible to determine whether PE led
389 to greater susceptibility to psoriatic disease or whether individuals with psoriatic
390 disease develop more PE. Patient-reported outcomes (PROMs) such as the
391 questionnaire application in an interview form may have potential interviewer
392 bias, however the extensive impact grading [from 0 (null) to 5 (maximum)] tends
393 to minimize this effect.

394 On the other hand, advantages can also be cited as (i) high number of
395 individuals in the sample, increasing the statistical power of the study, since
396 PSO has a low prevalence, making it difficult to obtain large samples; (ii) PSO
397 and PsA diagnosis by specialized physicians; (iii) full mouth periodontal
398 examination with robust criteria for PE definition, as it is recognized that the
399 quality of periodontal data and the criteria for defining PE strongly impacts the
400 results of association studies(46); and (iv) uniform methodology for clinical
401 assessment and questionnaire application. However, we highlight the need for

402 additional studies in different populations, with different study designs to expand
403 our knowledge on OHRQoL in psoriatic disease patients.

404 Thus, our study can be considered an important starting point for
405 investigations into OHRQoL PsA patients and the association between PE and
406 psoriatic disease, highlighting the inclusion of PE as another important
407 comorbidity associated mainly with PsA. Also, the need for attention to the oral
408 condition and its impacts of OHRQoL by both dentists and doctors of these
409 individuals who already present greater physical-emotional vulnerability is
410 advised.

411 Periodontists and dermatologists must broaden their clinical vision,
412 examining the oral cavity and dermatological lesions, providing a holistic view of
413 the individual. Multidisciplinary interaction is desirable to improve the impact of
414 these diseases on the QoL of individuals with psoriatic disease and PE.

415

416 **Conclusion**

417 This study demonstrated the negative impacts of PE on the OHRQoL
418 of the analyzed individuals, being PSO, mainly PsA and PE individuals
419 presenting significantly worse OHRQoL indicators.

420

421 **Acknowledgments**

422

423 This study was supported by the National Council for Scientific and
424 Technological Development - CNPq, Brazil (Productivity research grants n°
425 307034/2015-1; n° 307024/2015-6 and funding n° 402158/2016-4).

References

1. Tonetti MS, Greenwell H, Kornman KS. Staging and grading of periodontitis: Framework and proposal of a new classification and case definition. *J Clin Periodontol*. 2018;45:S149–61. DOI: [10.1111/jcpe.12945](https://doi.org/10.1111/jcpe.12945)
2. Cekici A, Kantarci A, Hasturk H, Van Dyke TE. Inflammatory and immune pathways in the pathogenesis of periodontal disease. *Periodontol 2000* . 2014;64(1):57–80. DOI: [10.1111/prd.12002](https://doi.org/10.1111/prd.12002)
3. Bunte K, Beikler T. Th17 Cells and the IL-23/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. *Int J Mol Sci* . 2019;20(14).
<https://doi.org/10.3390/IJMS20143394>
4. Linden GJ, Lyons A, Scannapieco FA. Periodontal systemic associations: review of the evidence. *J Clin Periodontol* . 2013;40:S8–19.
[doi.1111/jcpe.12064](https://doi.org/10.1111/jcpe.12064)
5. Sanz M, Marco del Castillo A, Jepsen S, Gonzalez-Juanatey JR, D’Aiuto F, Bouchard P, et al. Periodontitis and cardiovascular diseases: Consensus report. *J Clin Periodontol* . 2020;1,47(3):268–88.
DOI: [10.1111/jcpe.13189](https://doi.org/10.1111/jcpe.13189)
6. Ungprasert P, Wijarnpreecha K, Wetter D. Periodontitis and risk of psoriasis : a systematic review and. *J Eur Acad Dermatology Venereol*. 2017;31:857–62. DOI: [10.1111/jdv.14051](https://doi.org/10.1111/jdv.14051)
7. Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. *BMJ* . 2020; 28 ,369.
<https://doi.org/10.1136/BMJ.M1590>
8. Scotti L, Franchi M, Marchesoni A, Corrao G. Prevalence and incidence of psoriatic arthritis: A systematic review and meta-analysis. *Semin Arthritis Rheum* . 2018; 48(1):28–34. DOI: [10.1016/j.semarthrit.2018.01.003](https://doi.org/10.1016/j.semarthrit.2018.01.003)
9. Shah K, Paris M, Mellars L, Changolkar A, Mease PJ. Real-world burden

- of comorbidities in US patients with psoriatic arthritis. *RMD open* . 2017;3(2):e000588. DOI: [10.1136/rmdopen-2017-000588](https://doi.org/10.1136/rmdopen-2017-000588)
10. Dowlatshahi EA, Wakkee M, Arends LR, Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: A systematic review and meta-analysis. *J Invest Dermatol* . 2014;134(6):1542–51. DOI: [10.1038/jid.2013.508](https://doi.org/10.1038/jid.2013.508)
 11. Fleming P, Bai JW, Pratt M, Sibbald C, Lynde C, Gulliver WP. The prevalence of anxiety in patients with psoriasis : a systematic review of observational studies and clinical trials. *J Eur Acad Dermatol Venereol*. 2017;798–807. DOI: [10.1111/jdv.13891](https://doi.org/10.1111/jdv.13891)
 12. Egeberg A, Mallbris L, Gislason G, Hansen PR, Mrowietz U. Risk of periodontitis in patients with psoriasis and psoriatic arthritis. *J Eur Acad Dermatology Venereol* . 2017; 31(2):288–93. DOI: [10.1111/jdv.13814](https://doi.org/10.1111/jdv.13814)
 13. Mishra S, Johnson L, Agrawal S, Rajput S. Assessment of Periodontal status in Patients with Psoriatic Arthritis: A retrospective, case-control study. *J Clin Exp Dent* . 2021;13(8):776–83 DOI: [10.4317/jced.58125](https://doi.org/10.4317/jced.58125)
 14. Su N-Y, Huang J-Y, Hu C-J, Yu H-C, Chang Y-C. Increased risk of periodontitis in patients with psoriatic disease: a nationwide population-based retrospective cohort study. *PeerJ* . 2017;5:e4064. DOI: [10.7717/peerj.4064](https://doi.org/10.7717/peerj.4064)
 15. Zhang X, Gu H, Xie S, Su Y. Periodontitis in patients with psoriasis: A systematic review and meta-analysis. *Oral Dis*. 2022 Jan 1;28(1):33–43. DOI: [10.1111/odi.13617](https://doi.org/10.1111/odi.13617)
 16. Dalmády S, Kemény L, Antal M, Gyulai R. Periodontitis: a newly identified comorbidity in psoriasis and psoriatic arthritis . Vol. 16, *Expert Review of Clinical Immunology*. Taylor and Francis Ltd; 2020; p. 101–8. DOI: [10.1080/1744666X.2019.1700113](https://doi.org/10.1080/1744666X.2019.1700113)
 17. Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. *Curr Opin Rheumatol* . 2015 ;27(2):127–33. DOI: [10.1097/BOR.000000000000147](https://doi.org/10.1097/BOR.000000000000147)

18. Polineni S, Gopinath H, Ramani JR, Yadav S, Aravindakshan R, Yerragudi N, et al. The association of psoriasis and psoriatic arthritis with periodontitis: A hospital-based case-control study. *Indian J Dermatol Venereol Leprol* . 2023;0:1–5. DOI: [10.25259/IJDVL.331.2022](https://doi.org/10.25259/IJDVL.331.2022)
19. Mendes VS, Cota LOM, Costa AA, Oliveira AMSD, Costa FO. Periodontitis as another comorbidity associated with psoriasis: A case-control study. *J Periodontol* . 2019;1–9. Doi.10.1002/JPER.18-0394
20. Papantonopoulos GH. Effect of periodontal therapy in smokers and non-smokers with advanced periodontal disease: results after maintenance therapy for a minimum of 5 years. *J Periodontol* . 2004;75(6):839–43. DOI: [10.1902/jop.2004.75.6.839](https://doi.org/10.1902/jop.2004.75.6.839)
21. ADA. Classification and diagnosis of diabetes: Standards of medical care in Diabetesd2018. *Diabetes Care*. 2018;41:S13–27. DOI: [10.2337/dc18-S002](https://doi.org/10.2337/dc18-S002)
22. Tomar SL, Asma S. Smoking-Attributable Periodontitis in the United States: Findings From NHANES III. *J Periodontol*. 2000;71(5):743–51. DOI: [10.1902/jop.2000.71.5.743](https://doi.org/10.1902/jop.2000.71.5.743)
23. Adulyanon S, Vourapukjaru J, Sheiham A. Oral impacts affecting daily performance in a low dental disease Thai population. *Community Dent Oral Epidemiol*. 1996;24(6):385–9. DOI: [10.1111/j.1600-0528.1996.tb00884.x](https://doi.org/10.1111/j.1600-0528.1996.tb00884.x)
24. Abegg C, Fontanive VN, Tsakos G, Davoglio RS, de Oliveira MMC. Adapting and testing the oral impacts on daily performances among adults and elderly in Brazil. *Gerodontology* . 2015;32(1):46–52. DOI: [10.1111/ger.12051](https://doi.org/10.1111/ger.12051)
25. Silness J, Løe H. Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. *Acta Odontol Scand*. 1964;22(1):121–35. DOI: [10.3109/00016356408993968](https://doi.org/10.3109/00016356408993968)
26. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica* . 1978; 157(4):238–44. DOI: [10.1159/000250839](https://doi.org/10.1159/000250839)

27. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum* . 2006; 54(8):2665–73. DOI: [10.1002/art.21972](https://doi.org/10.1002/art.21972)
28. Fadel HT, Flytström I, Calander A-M, Bergbrant I-M, Heijl L, Birkhed D. Profiles of Dental Caries and Periodontal Disease in Individuals With or Without Psoriasis. *J Periodontol*. 2013;84(4):477–85. DOI: [10.1902/jop.2012.120119](https://doi.org/10.1902/jop.2012.120119)
29. Lazaridou E, Tsikrikoni A, Fotiadou C, Kyrmanidou E, Vakirlis E, Giannopoulou C, et al. Association of chronic plaque psoriasis and severe periodontitis: A hospital based case-control study. *J Eur Acad Dermatology Venereol*. 2013;27(8):967–72. DOI: [10.1111/j.1468-3083.2012.04615.x](https://doi.org/10.1111/j.1468-3083.2012.04615.x)
30. Moura MF, Cota LOM, Silva TA, Cortelli SC, Ferreira GA, López MM, et al. Clinical and microbiological effects of non-surgical periodontal treatment in individuals with rheumatoid arthritis: a controlled clinical trial. *Odontology* . 2021; 109(2):484–93. DOI: [10.1007/s10266-020-00566-0](https://doi.org/10.1007/s10266-020-00566-0)
31. Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K, et al. Immunopathogenesis of psoriasis. *Exp Dermatol*. 2007;16(10):779–98. Doi.10.1111/j.1600-0625.2007.00629.x
32. Sharma A, Raman A, Pradeep A. Association of chronic periodontitis and psoriasis: periodontal status with severity of psoriasis. *Oral Dis* . 2015;21(3):314–9. DOI:10.1111/odi.12271
33. Nakib S, Han J, Li T, Joshipura K, Qureshi AA. Periodontal disease and risk of psoriasis among nurses in the United States. *Acta Odontol Scand*. 2013;71(6):1423–9. DOI: [10.3109/00016357.2013.766360](https://doi.org/10.3109/00016357.2013.766360)
34. Koo J, Marangell LB, Nakamura M, Armstrong A, Jeon C, Bhutani T, et al. Depression and suicidality in psoriasis: review of the literature including the cytokine theory of depression. *J Eur Acad Dermatol Venereol* . 2017;31(12):1999–2009. DOI: [10.1111/jdv.14460](https://doi.org/10.1111/jdv.14460)

35. Verhoeven EWM, Kraaimaat FW, van de Kerkhof PCM, van Weel C, Duller P, van der Valk PGM, et al. Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. *Br J Dermatol* . 2007;156(6):1346–9. DOI:10.1111/j.1365-2133.2007.07916.x
36. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. *Ann Rheum Dis*. 2005;18–23. DOI: [10.1136/ard.2004.033217](https://doi.org/10.1136/ard.2004.033217)
37. Palijan T Žarkovi, Kovaevi D, Vlastelica M, Dadi-Hero E, Sarilar M. Quality of life of persons suffering from schizophrenia, psoriasis and physical disabilities. *Psychiatr Danub*. 2017;29(1):60–5. DOI: [10.24869/psyd.2017.60](https://doi.org/10.24869/psyd.2017.60)
38. Salman A, Yucelten AD, Sarac E, Saricam MH, Perdahlı-fis N. Impact of psoriasis in the quality of life of children, adolescents and their families : a cross-sectional study. *Ann Bras Dermatology*. 2018;93(6):819–23. doi: [10.1590/abd1806-4841.20186981](https://doi.org/10.1590/abd1806-4841.20186981)
39. Kamalaraj N, El-Haddad C, Hay P, Pile K. Systematic review of depression and anxiety in psoriatic arthritis. *Int J Rheum Dis* . 2019; 22(6):967–73. doi: 10.1111/1756-185X.13553.
40. Cunha-Cruz J, Hujoel PP, Kressin NR. Oral health-related quality of life of periodontal patients. *J Periodontal Res* . 2007;42(2):169–76. DOI:10.1111/j.1600-0765.2006.00930.x
41. Costa AA, Cota LOM, Mendes VS, Oliveira AMSD, Cyrino RM, Costa FO. Periodontitis and the impact of oral health on the quality of life of psoriatic individuals: a case-control study. *Clin Oral Investig* . 2021;25(5):2827–36. doi: 10.1007/s00784-020-03600-1
42. Needleman I, McGrath C, Floyd P, Biddle A. Impact of oral health on the life quality of periodontal patients. *J Clin Periodontol* . 2004; 31(6):454–7. DOI:10.1111/j.1600-051X.2004.00498.x
43. Wandera MN, Engebretsen IM, Rwenyonyi CM, Tumwine J, Åstrøm AN.

- Periodontal status, tooth loss and self-reported periodontal problems effects on oral impacts on daily performances, OIDP, in pregnant women in Uganda: A cross-sectional study. *Health Qual Life Outcomes*. 2009 Oct 14;7:89. doi: 10.1186/1477-7525-7-89.
44. Borges T de F, Regalo SC, Taba M, Siéssere S, Mestriner W, Semprini M. Changes in Masticatory Performance and Quality of Life in Individuals With Chronic Periodontitis. *J Periodontol* . 2013;84(3):325–31. doi: 10.1902/jop.2012.120069
45. Llanos AH, Benítez Silva CG, Ichimura KT, Rebeis ES, Giudicissi M, Romano MM, et al. Impact of aggressive periodontitis and chronic periodontitis on oral health-related quality of life. *Braz Oral Res* . 2018;32:e006. doi: 10.1590/1807-3107bor-2018.vol32.0006.
46. Costa FO, Guimarães AN, Cota LOM, Pataro AL, Segundo TK, Cortelli SC, et al. Impact of different periodontitis case definitions on periodontal research. *J Oral Sci*. 2009;51(2):199–206. doi: 10.2334/josnusd.51.19.

Tables and Figures

Table 1. Comparative analysis of variables of interest in the studied groups.

Table 2. Periodontal parameters of the studied groups.

Table 3. Comparison between groups in relation to frequency and severity for each OIDP item,

Table 4. Dichotomous influence of variables of interest on quality of life.

Table 5. Logistic regression of variables of interest associated with impacts on quality of life.

Table 6. Association analysis between quality of life and periodontal parameters.

Supporting Figure 1. Stratification of OIDP scores between groups

Table 1. Comparative analysis of variables of interest in the studied groups.

Variables	Group			A-B		A-C		B-C	
	Control (A) (n = 359)	Psoriasis (B) (n = 210)	Psoriatic arthritis (C) (n = 86)	p	OR CI (95%)	p	OR CI (95%)	p	OR CI (95%)
Gender									
Feminine	225 (62.7%)	128 (61.0%)	48 (55.81%)	0.683*	1	0.984*	1	0.768*	1
Masculine	134 (37.3%)	82 (39.0%)	38 (44.19%)		1.08 (0.76; 1.53)		1.00 (0.61; 1.62)		0.93 (0.55; 1.55)
Age (years)									
Mean ± s.d.	47.5 ± 5.1	49.7 ± 4.2	48.8 ± 4.3	<0.001 ‡	-	0.011 ‡	-	0.840‡	-
Income									
1-2 Brazilian Minimum Wage (BMW)	146 (40.7%)	84 (40.0%)	33 (38.4%)	0.439*	1	0.926*	1	0.636*	1
3-4 BMW	129 (35.9%)	85 (40.5%)	32 (37.2%)		1.15 (0.78; 1.68)		1.10 (0.64; 1.88)		0.96 (0.54; 1.7)
5 BMW or more	84 (23.4%)	41 (19.5%)	21 (24.4%)		0.85 (0.54; 1.34)		1.11 (0.6; 2.03)		1.3 (0.67; 2.53)
Educational level									
< 8 years	248 (69.1%)	144 (68.6%)	55 (64.0%)	0.899*	1	0.360*	1	0.442*	1
> 8 years	111 (30.9%)	66 (31.4%)	31 (36.0%)		1.02 (0.71; 1.48)		1.26 (0.77; 2.06)		1.23 (0.73; 2.08)
Smoking									
No	314 (87.5%)	183 (87.1%)	69 (80.2%)	0.911*	1	0.082*	1	0.129*	1
Yes	45 (12.5%)	27 (12.9%)	17 (19.8%)		1.03 (0.62; 1.72)		1.72 (0.93; 3.18)		1.67 (0.86; 3.25)
Alcohol consumption									
No	159 (44.3%)	93 (44.3%)	27 (31.4%)	0.999*	1	0.029*	1	0.040 *	1
Yes	200 (55.7%)	117 (55.7%)	59 (68.6%)		1.00 (0.71; 1.41)		1.74 (1.05; 2.87)		1.74 (1.02; 2.95)
Flossing									
No	200 (56.0%)	122 (58.1%)	51 (59.3%)	0.660*	1	0.582*	1	0.848*	1
Yes	157 (44.0%)	88 (41.9%)	35 (40.7%)		0.92 (0.65; 1.30)		0.87 (0.54; 1.41)		0.95 (0.57; 1.58)
Brushing									
1 time	12 (3.3%)	10 (4.8%)	6 (7.0%)	0.638*	1	0.303*	1	0.741†	1
2 times	104 (29.1%)	63 (30.0%)	25 (29.1%)		0.73 (0.30; 1.78)		0.48 (0.16; 1.41)		0.66 (0.22; 2.01)
3 or 4 times	242 (67.6%)	137 (65.2%)	55 (64.9%)		0.68 (0.29; 1.61)		0.82 (0.59; 1.14)		0.88 (0.59; 1.29)
Antidepressant use									
No	320 (89.9%)	172 (81.9%)	61 (70.9%)	0.006 *	1	<0.001 *	1	0.036 *	1

Yes	36 (10.1%)	38 (18.1%)	25 (29.1%)		1.96 (1.20; 3.21)		3.64 (2.04; 6.5)		1.86 (1.04; 3.32)
Anxiolytics use									
No	306 (86.4%)	161 (77.8%)	65 (75.6%)	0.008*	1	0.013*	1	0.684*	1
Yes	48 (13.6%)	46 (22.2%)	21 (24.4%)		1.82 (1.16; 2.85)		2.06 (1.15; 3.67)		1.13 (0.63; 2.04)
Diabetes									
No	333 (93.0%)	180 (85.7%)	71 (82.6%)	0.004*	1	0.002*	1	0.492*	1
Yes	25 (7.0%)	30 (14.3%)	15 (17.4%)		2.22 (1.27; 3.89)		2.81 (1.41; 5.61)		1.27 (0.64; 2.5)
Body mass index									
Mean ± s.d.	24.8 ± 1.8	25.8 ± 2.2	26.6 ± 3.1	<0.001‡	-	<0.001‡	-	0.055‡	-
Quality of life									
Mean ± s.d.	3.3 ± 6.4	12.6 ± 25.5	14.6 ± 27.0	0.052§	-	0.011 §	-	0.322‡	-
Quality of life									
Not impacted	243 (67.7%)	134 (63.8%)	49 (57.0%)			0.060*		0.272*	
Impacted	116 (32.3%)	76 (36.2%)	37 (43.0%)	0.345*	1		1		1
					1.19 (0.83; 1.70)		1.58 (0.98; 2.56)		1.33 (0.8; 2.22)

Chi-square test (*), Fisher's exact test (†), Student's t-test (‡) and Mann-Whitney test (§). Significant values in bold.

[number of teeth (%)]									
< 3mm	219 (2.5%)	174 (3.5%)	37 (1.8%)						
3 to 6 mm	7,583 (88.1%)	4,336 (86.5%)	1,701 (81.5%)	0.002*	1	<0.001*	1	<0.001*	1
> 6mm	800 (9.3%)	506 (10.1%)	350 (16.8%)		0.72 (0.59; 0.88)		1.33 (0.93; 1.89)		1.84 (1.29; 2.64)
CAI (mm)					0.80 (0.63; 1.00)		2.59 (1.79; 3.75)		3.25 (2.22; 4.76)
Mean ± s.d	3.4 ± 0.7	3.9 ± 0.6	4.1 ± 0.6	<0.001†	-	<0.001†	-	0.004†	-
% bleeding surfaces									
Mean ± s.d	39.7 ± 14.4	43.7 ± 17.5	50.9 ± 15.8	0.034†	-	<0.001†	-	<0.001†	-
% bleeding teeth									
Mean ± s.d	62.1 ± 19.3	61.7 ± 16.8	68.0 ± 16.2	0.821†	-	0.007†	-	0.002†	-
Plaque Index									
Mean ± s.d	39.4 ± 11.1	40.6 ± 10.0	44.9 ± 11.3	0.101†	-	<0.001†	-	0.001†	-

Chi-square test (*) and Student's t test (†). probing depth (PD), clinical attachment level (CAL). Significant values in bold.

Table 3. Comparison between groups in relation to frequency and severity for each OIDP item

OIDP	Control		Psoriasis		Psoriatic arthritis	
	-PE	+PE	-PE	+PE	-PE	+PE
Frequency						
Eating	0.46 (0.35; 0.58)	0.47 (0.29; 0.67)	0.43 (0.30; 0.57)	2.10 (1.60; 2.58)	0.59 (0.33; 0.86)	1.78 (1.16; 2.39)
Speaking	0.04 (0.01; 0.08)	0.22 (0.13; 0.32)	0.07 (0.03; 0.12)	1.40 (0.97; 1.87)	0.05 (0.00; 0.14)	0.94 (0.45; 1.43)
Tooth cleaning	0.30 (0.21; 0.40)	0.52 (0.34; 0.72)	0.30 (0.18; 0.43)	2.17 (1.72; 2.65)	0.32 (0.08; 0.59)	1.41 (0.84; 1.98)
Smiling	0.33 (0.24; 0.43)	0.11 (0.03; 0.21)	0.10 (0.05; 0.17)	0.42 (0.17; 0.75)	0.19 (0.08; 0.32)	0.76 (0.33; 1.29)
Sleeping	0.00 (0.00; 0.00)	0.22 (0.11; 0.35)	0.02 (0.10; 0.33)	0.72 (0.39; 1.11)	0.27 (0.05; 0.51)	0.65 (0.24; 1.06)
Maintaining emotional state	0.01 (0.00; 0.04)	0.34 (0.18; 0.53)	0.19 (0.09; 0.30)	0.67 (0.31; 1.04)	0.16 (0.00; 0.38)	0.18 (0.00; 0.47)
Activities	0.01 (0.00; 0.03)	0.08 (0.03; 0.13)	0.09 (0.03; 0.17)	0.25 (0.07; 0.49)	0.30 (0.05; 0.57)	0.24 (0.00; 0.57)
Leisure	0.18 (0.12; 0.24)	0.17 (0.09; 0.25)	0.23 (0.14; 0.33)	0.72 (0.39; 1.12)	0.51 (0.27; 0.78)	0.37 (0.08; 0.73)
Gravity						
Eating	0.57 (0.45; 0.7)	0.61 (0.43; 0.82)	0.49 (0.28; 0.70)	2.10 (1.63; 2.57)	0.86 (0.43; 1.38)	1.59 (1.04; 2.16)
Speaking	0.03 (0.00; 0.06)	0.38 (0.24; 0.54)	0.38 (0.24; 0.56)	1.40 (0.97; 1.87)	0.49 (0.22; 0.81)	1.04 (0.53; 1.53)

Tooth cleaning	0.20 (0.12; 0.28)	0.61 (0.41; 0.81)	0.28 (0.16; 0.42)	2.03 (1.60; 2.50)	0.32 (0.08; 0.65)	1.22 (0.73; 1.71)
Smiling	0.45 (0.34; 0.57)	0.17 (0.07; 0.30)	0.38 (0.22; 0.54)	0.44 (0.17; 0.78)	0.41 (0.14; 0.73)	0.65 (0.24; 1.14)
Sleeping	0.00 (0.00; 0.00)	0.25 (0.12; 0.39)	0.09 (0.02; 0.17)	0.69 (0.36; 1.07)	0.24 (0.03; 0.49)	0.65 (0.24; 1.06)
Maintaining emotional state	0.03 (0.00; 0.06)	0.42 (0.26; 0.60)	0.20 (0.10; 0.33)	0.61 (0.28; 0.94)	0.35 (0.11; 0.65)	0.16 (0.00; 0.41)
Activities	0.01 (0.00; 0.03)	0.14 (0.07; 0.24)	0.17 (0.07; 0.30)	0.33 (0.11; 0.61)	0.11 (0.00; 0.27)	0.24 (0.00; 0.57)
Leisure	0.30 (0.19; 0.40)	0.37 (0.22; 0.52)	0.17 (0.06; 0.30)	0.93 (0.56; 1.38)	0.24 (0.05; 0.49)	0.78 (0.33; 1.22)

*Bootstrap range. The values marked in bold indicate the non-overlapping CIs comparing the groups with and without periodontal disease, that is, those with significant differences.

Table 4. Dichotomous influence of variables of interest on quality of life

Variables	Quality of life		p
	Not impacted (n = 426)	Impacted (n = 229)	
Diabetes			
Yes	40 (57.1%)	30 (42.9%)	0.146*
No	385 (65.9%)	199 (34.1%)	
Body mass index			
Mean ± s.d	25.3 ± 2.2	25.5 ± 2.3	0.253†
Smoking			
Yes	59 (66.3%)	30 (33.7%)	0.790*
No	367 (64.8%)	199 (35.2%)	
Alcohol consumption			
Yes	222 (59.0%)	154 (41.0%)	<0.001*
No	204 (73.1%)	75 (26.9%)	
Flossing			
Yes	179 (63.9%)	101 (36.1%)	0.642*
No	245 (65.7%)	128 (34.3%)	
Brushing			
1 time	16 (57.1%)	12 (42.9%)	0.270*
2 times	118 (61.5%)	74 (38.5%)	
Three times	291 (67.1%)	143 (32.9%)	
Antidepressant use			
Yes	63 (63.6%)	36 (36.4%)	0.779*
No	360 (65.1%)	193 (34.9%)	
Anxiolytics use			
Yes	58 (50.4%)	57 (49.6%)	<0.001*
No	360 (67.7%)	172 (32.3%)	
Gender			
Feminine	274 (67.3%)	133 (32.7%)	0.116*
Masculine	152 (61.3%)	96 (38.7%)	
Age (years)			
Mean ± s.d	48.4 ± 5.0	48.2 ± 4.4	0.645**
Income			
1-2 BMW	166 (63.1%)	97 (36.9%)	
3-4 BMW	173 (70.3%)	73 (29.7%)	
5 BMW or more	87 (59.6%)	59 (40.4%)	0.069*
Educational level			
< 8 years	300 (67.1%)	147 (32.9%)	
> 8 years	126 (60.6%)	82 (39.4%)	
Smoking			
Yes	59 (66.3%)	30 (33.7%)	0.102*
No	367 (64.8%)	199 (35.2%)	0.790*
Periodontitis			
Yes	130(30.5%)	110 (48.0%)	<0.001*
No	296 (69.5%)	119 (52%)	
Group			
PE+ control	74 (62.2%)	45 (37.8%)	0.121*
Psoriatic Arthritis +PE	27 (55.1%)	22 (44.9%)	0.826*
PE+ psoriasis	29 (40.3%)	43 (59.7%)	<0.001*

*Chi-Square Test and Student's t test (†). Brazilian Minimum Wage (BMW). Significant values in bold.

Table 5. Logistic regression of variables of interest associated with impacts on quality of life

Variables	Full model			Final model		
	β	p	OR (95% CI)	β	p	OR (95% CI)
Gender (Ref. Female)						
Masculine	0.21	0.247	1.23 (0.87; 1.74)			
Income (Ref. 3 to 4 BMW)						
1 to 2 BMW	0.24	0.222	1.28 (0.86; 1.89)	0.27	0.164	1.32 (0.89; 1.94)
5 BMW or more	0.58	0.011	1.78 (1.14; 2.80)	0.57	0.011	1.78 (1.14; 2.77)
Educational level (ref. < 8 years)						
> 8 years	0.39	0.038	1.47 (1.02; 2.13)			
Alcohol consumption (Ref. No)						
Yes	0.53	0.004	1.69 (1.19; 2.42)	0.56	0.002	1.74 (1.23; 2.47)
Anxiolytics use (Ref. No)						
Yes	0.72	0.001	2.05 (1.32; 3.18)	0.66	0.002	1.93 (1.26; 2.95)
Diabetes (Ref. No)						
Yes	0.44	0.112	1.55 (0.90; 2.66)			
Body mass index	-0.03	0.531	0.97 (0.90; 1.06)	-	-	-
Group (Ref. Control)						
Psoriasis	0.12	0.537	1.13 (0.77; 1.67)			
Psoriatic arthritis	0.15	0.586	1.16 (0.68; 1.96)	-	-	-
Periodontitis (Ref. No)						
Yes	0.66	< 0.001	1.93 (1.34; 2.78)	0.65	< 0.001	1.92 (1.36; 2.71)


Hosmes-Lemeshow test ($p = 0.170$) / AOC = 0.645 / Sensitivity = 0.245 / Specificity = 0.938 / Pseudo R2 = 9.3%. Brazilian Minimum Wage (BMW). Significant values in bold

Table 6. Association analysis between quality of life and periodontal parameters

Variables	Quality of life		p
	Not impacted (n = 426)	Impacted (n = 229)	
Periodontitis			
Yes	130 (54.2%)	110 (45.8%)	< 0.001*
No	296 (71.3%)	119 (28.7%)	
Number of teeth			
Mean ± s.d	23.9 ± 3.0	24.1 ± 2.7	0.558†
PD [number of sites (%)]			
< 3mm	16,967 (41.6%)	8,631 (39.1%)	< 0.001*
3 to 6 mm	22,959 (56.4%)	12,776 (57.8%)	
> 6mm	803 (2.0%)	685 (3.1%)	
PD [number of teeth (%)]			
< 3mm	2,932 (28.8%)	1,438 (26.0%)	< 0.001*
3 to 6 mm	6,755 (66.3%)	3,640 (65.9%)	
> 6mm	495 (4.9%)	445 (8.1%)	
PD (mm)			
Mean ± s.d	3.0 ± 0.6	3.2 ± 0.8	< 0.001†
CAL [number of sites (%)]			
< 3mm	3,626 (8.9%)	276 (2.7%)	
3 to 6 mm	35,785 (87.8%)	9,050 (88.9%)	< 0.001 *
> 6mm	1,325 (3.3%)	858 (8.4%)	
CAL [number of teeth (%)]			
< 3mm	276 (2.7%)	154 (2.8%)	< 0.001*
3 to 6 mm	9,050 (88.9%)	4,570 (82.8%)	
> 6mm	858 (8.4%)	798 (14.5%)	
CAL (mm)			
Mean ± s.d	3.6 ± 0.7	3.8 ± 0.8	< 0.001†
% bleeding surfaces			
Mean ± s.d	41.2 ± 15.7	44.8 ± 16.6	0.005†
% bleeding teeth			
Mean ± s.d	61.4 ± 18.3	65.3 ± 17.9	0.006†
Plaque index			
Mean ± s.d	39.7 ± 10.7	41.9 ± 11.2	0.002†

Chi-square test (*) and Mann-Whitney test (†); probing depth (PD); clinical attachment level (CAL). Significant values in bold.

Supporting Figure 1. Stratification of OIDP scores between groups



n= 655; $p < 0.001$ (Chi-square test). Note: The higher the OIDP, the worse the quality of life.